Abstract
Malignancy can be accompanied by rheumatologic clinical findings, and these can occur prior to, concurrently with, or after a diagnosis of cancer. Certain clinical information helps to differentiate paraneoplastic symptoms from those more characteristic of classic rheumatologic disorders such as rheumatoid arthritis or systemic lupus erythematosus. Clinicians need to have a higher level of suspicion for malignancy in a patient with rheumatologic manifestations in certain populations. This may be the case in patients with a personal or family history of malignancy, atypical presentations of rheumatologic disorders, and certain clinical situations (such as hypertrophic osteoarthropathy, carcinoma polyarthritis, dermatomyositis, and unilateral sacroiliitis). The current standard of care for patients with a rheumatologic disorder with a known paraneoplastic association (i.e., dermatomyositis) is age-appropriate cancer screening. This review is designed to guide the physician to musculoskeletal signs and symptoms that may be paraneoplastic in origin. Additionally, when the clinician understands current information regarding malignant associations, it will help them decide when it may be appropriate to pursue further investigative work-up or evaluate for recurrence of a known primary tumor.
Keywords: neoplastic process, Hypertrophic osteoarthropathy, Vasculitis, Dermatomyositis, lymphoma
Current Cancer Therapy Reviews
Title: Update on the Rheumatologic Manifestations of Malignancy
Volume: 3 Issue: 3
Author(s): Lianne Marks, Clifton D. Fuller, Parag Sanghvi, Melva Pinn and Charles R. Thomas
Affiliation:
Keywords: neoplastic process, Hypertrophic osteoarthropathy, Vasculitis, Dermatomyositis, lymphoma
Abstract: Malignancy can be accompanied by rheumatologic clinical findings, and these can occur prior to, concurrently with, or after a diagnosis of cancer. Certain clinical information helps to differentiate paraneoplastic symptoms from those more characteristic of classic rheumatologic disorders such as rheumatoid arthritis or systemic lupus erythematosus. Clinicians need to have a higher level of suspicion for malignancy in a patient with rheumatologic manifestations in certain populations. This may be the case in patients with a personal or family history of malignancy, atypical presentations of rheumatologic disorders, and certain clinical situations (such as hypertrophic osteoarthropathy, carcinoma polyarthritis, dermatomyositis, and unilateral sacroiliitis). The current standard of care for patients with a rheumatologic disorder with a known paraneoplastic association (i.e., dermatomyositis) is age-appropriate cancer screening. This review is designed to guide the physician to musculoskeletal signs and symptoms that may be paraneoplastic in origin. Additionally, when the clinician understands current information regarding malignant associations, it will help them decide when it may be appropriate to pursue further investigative work-up or evaluate for recurrence of a known primary tumor.
Export Options
About this article
Cite this article as:
Lianne Marks , Clifton D. Fuller , Parag Sanghvi , Melva Pinn and Charles R. Thomas , Update on the Rheumatologic Manifestations of Malignancy, Current Cancer Therapy Reviews 2007; 3 (3) . https://dx.doi.org/10.2174/157339407781368378
| DOI https://dx.doi.org/10.2174/157339407781368378 |
Print ISSN 1573-3947 |
| Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current Progress in Protein Degradation and Cancer Therapy
Targeted Protein Degradation is gaining momentum in cancer therapy; it facilitates targeting undruggable proteins, overcomes cancer resistance, and avoids undesirable side effects. Thus small molecule degraders have emerged as novel therapeutic strategies. Targeted protein degradation (TPD), the process of eliminating a protein of interest holds a great promise for the ...read more
Current Status of Regulatory T Cells in Tumor Immune Escape and Immunotherapy
Regulatory T cells (Tregs) are a class of immunoregulatory suppressor cells characterized by the expression of CD4, CD25, and the transcription factor Forkhead box P3 (Foxp3). It plays an important role in maintaining immune homeostasis and inducing immune tolerance, and its dysfunction directly leads to the imbalance of immune homeostasis. ...read more
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Imino-Sugar-Based Nucleosides
Current Topics in Medicinal Chemistry Interrelationship Between Periapical Lesion and Systemic Metabolic Disorders
Current Pharmaceutical Design Protective Potential of Uric Acid, Folic Acid, Glutathione and Ascorbic Acid Against the Formation of Toxic Met-Myoglobin
Protein & Peptide Letters Active Tumor Targeting of Nanomaterials Using Folic Acid, Transferrin and Integrin Receptors
Current Drug Discovery Technologies Synthetic and Mechanistic Study on the Microwave Assisted Fries Rearrangement of 1-Methylidene-3,4-dihydroisoquinoline-2(1H)-yl-methanones
Current Organic Chemistry NLRP3 Is Involved in Ischemia/Reperfusion Injury
CNS & Neurological Disorders - Drug Targets Novel Formulation Approaches used for the Management of Osteoarthritis: A Recent Review
Current Drug Delivery Smart Nanoengineered Polymeric Capsules as Ideal Pharmaceutical Carriers
Current Organic Chemistry The Role of Leukocyte Immunoglobulin-Like Receptors Focusing on the Therapeutic Implications of the Subfamily B2
Current Drug Targets Non-steroidal Anti-inflammatory Drugs and Cyclooxygenase in Alzheimer s Disease
Current Drug Targets RNA-based Therapeutics: Master Regulator for Bioengineering Systems in Medicine World
Current Biotechnology Rheumatoid Arthritis in Southern Europe: Epidemiological, Clinical, Radiological and Genetic Considerations
Current Rheumatology Reviews The Gut Microbiota and the Emergence of Autoimmunity: Relevance to Major Psychiatric Disorders
Current Pharmaceutical Design Chemokines and Persistent Inflammation in Rheumatoid Arthritis: Hunting for Therapeutic Targets
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Contribution of Dietary Factors to Peroxisome Proliferator-Activated Receptor-Mediated Inflammatory Signaling in Arthritic Diseases
Current Rheumatology Reviews Curcumin and its Derivatives Targeting Multiple Signaling Pathways to Elicit Anticancer Activity: A Comprehensive Perspective
Current Medicinal Chemistry Influencing Factors in Tunisian Rheumatoid Arthritis Patients’ Quality of Life: Burden and Solutions
Current Rheumatology Reviews Altered Hyaluronan Biosynthesis and Cancer Progression: an Immunological Perspective
Mini-Reviews in Medicinal Chemistry Intrathecal Rituximab Therapy in Multiple Sclerosis: Review of Evidence Supporting the Need for Future Trials
Current Drug Targets New Insights into Adipokines as Potential Biomarkers for Type-2 Diabetes Mellitus
Current Medicinal Chemistry





